KIM DENNIS D

CIK 00014567504 companiesLA JOLLA, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001456750

Recent Transactions

39 trades

Sale
CymaBay Therapeutics, Inc.
Common Stock
2023-04-17$9.54/sh−112,219→ 20,000 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2023-04-17$4.37/sh+112,219→ 132,219 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2023-04-17−112,219→ 169,900 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2023-04-13−7,781→ 282,119 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2023-04-13$4.37/sh+7,781→ 27,781 total
Sale
CymaBay Therapeutics, Inc.
Common Stock
2023-04-13$8.98/sh−7,781→ 20,000 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2023-03-28−100→ 289,900 total
Exercise/Conversion
CymaBay Therapeutics, Inc.
Common Stock
2023-03-28$4.37/sh+100→ 20,100 total
Sale
CymaBay Therapeutics, Inc.
Common Stock
2023-03-28$8.98/sh−100→ 20,000 total
Award
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2023-01-25+180,000→ 180,000 total
Award
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2022-01-25+133,333→ 133,333 total
Purchase
CymaBay Therapeutics, Inc.
Common Stock
2022-01-19$3.04/sh+20,000→ 20,000 total
Award
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2021-05-17+390,000→ 390,000 total
Award
CymaBay Therapeutics, Inc.
Employee Stock Option (right to buy)
2021-05-17+10,000→ 10,000 total
Award
Skye Bioscience, Inc.$SKYE
Employee Stock Option (Right to Buy)
2020-08-07+4,000,000→ 4,736,541 total
Award
Skye Bioscience, Inc.$SKYE
Employee Stock Options (Right to Buy)
2019-08-21+736,541→ 736,541 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2019-01-22+95,000→ 95,000 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2018-02-22+125,000→ 125,000 total
Purchase
Larimar Therapeutics, Inc.$LRMR
Common Stock
2017-07-11$3.39/sh+10,000→ 21,443 total
Purchase
Larimar Therapeutics, Inc.$LRMR
Common Stock
2017-05-11$4.40/sh+9,800→ 11,443 total
Purchase
Larimar Therapeutics, Inc.$LRMR
Common Stock
2017-05-10$4.40/sh+200→ 1,643 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2017-01-27+88,000→ 88,000 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2016-03-31+37,500→ 37,500 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2016-03-31+75,000→ 75,000 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-17$1.57/sh+9,142→ 9,142 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-17$40.00/sh−9,142→ 0 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-17$40.00/sh−9,142→ 0 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2015-09-17−9,142→ 103,312 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-15$40.00/sh−30,265→ 0 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2015-09-15−30,265→ 112,454 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-15$40.00/sh−30,265→ 0 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-15$1.57/sh+30,265→ 30,265 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-14$40.00/sh−593→ 0 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2015-09-14−593→ 142,719 total
Sale
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-14$40.00/sh−593→ 0 total
Exercise/Conversion
Larimar Therapeutics, Inc.$LRMR
Common Stock
2015-09-14$1.57/sh+593→ 593 total
Award
Larimar Therapeutics, Inc.$LRMR
Stock Option (Right to Buy)
2015-02-27+90,000→ 281,509 total
Award
Orexigen Therapeutics, Inc.
Stock option (right to buy)
2009-04-23+44,936→ 44,936 total
Award
Orexigen Therapeutics, Inc.
Common Stock
2009-03-24$2.65/sh+10,000→ 25,200 total

Companies

Recent Filings

Address

C/O OREXIGEN THERAPEUTICS, INC. 3344 N. TORREY PINES COURT, SUITE 200

LA JOLLA, CA, 92037

View on SEC.gov